UNSPSC 51342001: Capravirine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C20H20Cl2N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VHC779598X, chemically known as 5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(pyridin-4-yl-methyl)-1h-imidazol-2-yl-methyl carbamate but generally known as capravirine, which bears US NIH Compound Identifier 1783. European Medicines Agency schedules Capravirine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20328.

UNSPSC 51342001 Capravirine, a Commodity code, does not align with the state and local procurement activity currently posted under this classification. The recent opportunities tagged to this code—Naloxone and drug deactivation systems, therapeutic pharmacy initiatives, medical and first aid supplies for emergency responders, and generic pharmaceuticals and OTC products—span naloxone procurement, pharmacy benefit management, emergency medical consumables, and multi-source generic drugs, none of which are capravirine (an antiretroviral medication for HIV treatment). The code shows a fundamental mismatch between its nominal scope and what state and local governments are actually soliciting.

Recent activity spans health departments, emergency services, and state pharmacy programs across multiple jurisdictions. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; the City of Tampa issued an ITB for medical and first aid supplies for its Fire Department Rescue Division (26P00145) in March 2026 with an estimated contract value of $700,000.00 and a Small Local Business Enterprise set-aside; the Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with awards effective July 1, 2026. These opportunities suggest the code may be incorrectly applied or used as a catch-all for various pharmaceutical and medical supply purchases by state health agencies, counties, municipalities, and cooperative purchasing organizations, rather than reflecting actual capravirine procurement.